Board of Directors
Board of Directors
Christopher Locher, PhD
Dr. Locher is the CEO and Co-Founder and has over 20 years of biopharmaceutical industry experience developing new vaccines and therapeutics for multiple diseases. Prior to Versatope, he was a Senior Director at Vertex Pharmaceuticals in Boston where he held leadership and management roles in large infectious disease R&D programs and international collaborations.
Jim Kuo, MD, MBA
Dr. Kuo has over 25 years of experience in senior leadership roles in pharmaceutical business development. He has played key roles in leading venture capital financing, strategic partnerships, licensing and strategic planning in the genomics, small molecule, biotherapy, monoclonal antibody and inflammatory disease. He is currently the Chairman of the Board of Immunoprecise Antibodies and Monarch Labs.
Brenda McCabe, MBA
Ms. McCabe has over 25 years experience in senior operating roles in domestic and international markets in VP positions in Sales, Operations, Business development in pharmaceuticals at AstraZeneca; clean technology at Infinia Corporation and retail and consulting with McKinsey & Company. Over the last eight years she has worked in regulated industries – pharmaceuticals, digital health and energy and is a NACD Governance Fellow. Since 2012 she has served as an Independent Board Director on privately held and public company Boards in the US and Spain. From her own firm, she provides advisory and consulting services for small and medium size enterprises (SMEs) in the areas of technology.
Matt DeLisa, PhD
Dr. DeLisa is a Co-Founder of and the William L. Lewis Professor of Engineering at Cornell University. His research team focuses on the molecular machines of protein biosynthesis both as a toolbox for the discovery, design and manufacturing of biopharmaceuticals and as targets for reprogramming cellular physiology.
Dave Putnam, PhD
Dr. Putnam is also a Co-Founder of Versatope Therapeutics and Professor of Bioengineering at Cornell University. He has worked in the field of drug delivery and formulation of biomaterials for over 20 years. He and his collaborators have pioneered the development of probiotic exosomes and generated the strong preliminary data to support our preclinical development.